Chimeric Antigen Receptor (CAR) T-Cell Therapy for Patients with Lung Cancer: Current Perspectives

References

• Kocarnik JM, Compton K, Dean FE, et al.; Global Burden of Disease Cancer C. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019. JAMA Oncol. 2022;8(3):420–444.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.
   PubMed Web of Science ®Google Scholar
• Maher J. Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol. 2012;2012:278093.
   PubMedGoogle Scholar
• Koukourakis IM, Giatromanolaki A, Mitrakas A, Koukourakis MI. Loss of HLA-class-I expression in non-small-cell lung cancer: association with prognosis and anaerobic metabolism. Cell Immunol. 2022;373:104495.
   PubMed Web of Science ®Google Scholar
• Ichinokawa K, Nakanishi Y, Hida Y, et al. Downregulated expression of human leukocyte antigen class I heavy chain is associated with poor prognosis in non-small-cell lung cancer. Oncol Lett. 2019;18(1):117–126.
   PubMed Web of Science ®Google Scholar
• Gettinger S, Choi J, Hastings K, et al. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discov. 2017;7(12):1420–1435.
   PubMed Web of Science ®Google Scholar
• Kuwana Y, Asakura Y, Utsunomiya N, et al. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun. 1987;149(3):960–968.
   PubMed Web of Science ®Google Scholar
• Halim L, Maher J. CAR T-cell immunotherapy of B-cell malignancy: the story so far. Ther Adv Vaccines Immunother. 2020;8:2515135520927164.
   Google Scholar
• Biltibo E, Berdeja JG. SOHO State-of-the-Art Updates and Next Questions | BCMA-Directed CAR T-Cells: early Results and Future Directions. Clin Lymphoma Myeloma Leuk. 2023:45.
   Google Scholar
• Maher J. Solid tumours: building bridges to CAR-T success. Clin Translational Discovery. 2023;3:e179.
   Google Scholar
• Want MY, Bashir Z, Najar RA. T cell based immunotherapy for cancer: approaches and strategies. Vaccines. 2023;11(4):56.
   Web of Science ®Google Scholar
• Li H, Huang Y, Jiang DQ, et al. Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice. Cell Death Dis. 2018;9(2):177.
   PubMed Web of Science ®Google Scholar
• Zhou X, Li J, Wang Z, et al. Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes. Neoplasia. 2013;15(5):544–553.
   PubMed Web of Science ®Google Scholar
• Tran QT, Kennedy LH, Leon Carrion S, et al. EGFR regulation of epidermal barrier function. Physiol Genomics. 2012;44(8):455–469.
   PubMed Web of Science ®Google Scholar
• Whilding LM, Halim L, Draper B, et al. CAR T-Cells Targeting the Integrin alphavbeta6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies. Cancers. 2019;11(5):674.
   PubMed Web of Science ®Google Scholar
• Li G, Guo J, Zheng Y, et al. CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells. Mol Ther Oncolytics. 2021;22:507–517.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang Y, Pan H, et al. Chemokine Receptors CCR6 and PD1 Blocking scFv E27 Enhances Anti-EGFR CAR-T Therapeutic Efficacy in a Preclinical Model of Human Non-Small Cell Lung Carcinoma. Int J Mol Sci. 2023;24(6):5424.
   PubMed Web of Science ®Google Scholar
• Han X, Cinay GE, Zhao Y, Guo Y, Zhang X, Wang P. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering. Mol Ther. 2017;25(11):2466–2476.
   PubMed Web of Science ®Google Scholar
• Okamoto I, Kenyon LC, Emlet DR, et al. Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci. 2003;94(1):50–56.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Jiang J, Wu X, et al. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy. Front Med. 2019;13(1):57–68.
   PubMed Web of Science ®Google Scholar
• O’Rourke DM, Nasrallah MP, Desai A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399):eaaa0984.
   PubMed Web of Science ®Google Scholar
• Min J, Long C, Zhang L, et al. c-Met specific CAR-T cells as a targeted therapy for non-small cell lung cancer cell A549. Bioengineered. 2022;13(4):9216–9232.
   PubMed Web of Science ®Google Scholar
• Thayaparan T, Petrovic RM, Achkova DY, et al. CAR T-cell immunotherapy of MET-expressing malignant mesothelioma. Oncoimmunology. 2017;6(12):e1363137.
   PubMed Web of Science ®Google Scholar
• Maher J, Davies DM. CAR Based Immunotherapy of Solid Tumours-A Clinically Based Review of Target Antigens. Biology. 2023;12(2):287.
   PubMedGoogle Scholar
• Tchou J, Zhao Y, Levine BL, et al. Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. Cancer Immunol Res. 2017;5(12):1152–1161.
   PubMed Web of Science ®Google Scholar
• Wang WZ, Shilo K, Amann JM, et al. Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung. Cell Death Dis. 2021;12(6):577.
   PubMed Web of Science ®Google Scholar
• Baldwin ET, Gotte M, Tchesnokov EP, et al. Human endogenous retrovirus-K (HERV-K) reverse transcriptase (RT) structure and biochemistry reveals remarkable similarities to HIV-1 RT and opportunities for HERV-K-specific inhibition. Proc Natl Acad Sci U S A. 2022;119(27):e2200260119.
   PubMed Web of Science ®Google Scholar
• Balakrishnan A, Goodpaster T, Randolph-Habecker J, et al. Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues. Clin Cancer Res. 2017;23(12):3061–3071.
   PubMed Web of Science ®Google Scholar
• Kipps TJ. ROR1: an orphan becomes apparent. Blood. 2022;140(14):1583–1591.
   PubMed Web of Science ®Google Scholar
• Berger C, Sommermeyer D, Hudecek M, et al. Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunol Res. 2015;3(2):206–216.
   PubMed Web of Science ®Google Scholar
• Wallstabe L, Gottlich C, Nelke LC, et al. ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. JCI Insight. 2019;4(18):8754.
   Web of Science ®Google Scholar
• Maher J, Davies DM. CAR-Based Immunotherapy of Solid Tumours-A Survey of the Emerging Targets. Cancers. 2023;15(4):1171.
   PubMed Web of Science ®Google Scholar
• Cao B, Liu M, Wang L, et al. Remodelling of tumour microenvironment by microwave ablation potentiates immunotherapy of AXL-specific CAR T cells against non-small cell lung cancer. Nat Commun. 2022;13(1):6203.
   PubMed Web of Science ®Google Scholar
• Zhong M, Chalbatani GM, Deng M, et al. Functional characterization and development of novel human kinase insert domain receptor chimeric antigen receptor T-cells for immunotherapy of non-small cell lung cancer. Eur J Pharm Sci. 2023;180:106331.
   PubMed Web of Science ®Google Scholar
• Li N, Liu S, Sun M, et al. Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-Small Cell Lung Cancer. Transl Oncol. 2018;11(1):11–17.
   PubMed Web of Science ®Google Scholar
• Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2012;76(2):138–143.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Abken H. CAR T Cells Releasing IL-18 Convert to T-Bet(high) FoxO1(low) Effectors that Exhibit Augmented Activity against Advanced Solid Tumors. Cell Rep. 2017;21(11):3205–3219.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Li W, Zhelev DV, Mellors JW, Dimitrov DS, Baek DS. Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates. Front Oncol. 2023;13:1124039.
   PubMed Web of Science ®Google Scholar
• Thistlethwaite FGD, Guest R, Rothwell D, et al. The clinical efficacy of first‑generation carcinoembryonic antigen (CEACAM5)‑specific CAR T cells is limited by poor persistence and transient pre‑conditioning‑dependent respiratory toxicity. Cancer Immunol Immunother. 2017;66:1425–1436.
   PubMed Web of Science ®Google Scholar
• Li K, Pan X, Bi Y, et al. Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma. Oncotarget. 2016;7(3):2496–2507.
   PubMedGoogle Scholar
• Hickman TL, Choi E, Whiteman KR, et al. BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity. PLoS One. 2022;17(5):e0266980.
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Sho M, Tojo T, et al. Clinical significance of prostate stem cell antigen expression in non-small cell lung cancer. Jpn J Clin Oncol. 2010;40(4):319–326.
   PubMed Web of Science ®Google Scholar
• Wei X, Lai Y, Li J, et al. PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells. Oncoimmunology. 2017;6(3):e1284722.
   PubMed Web of Science ®Google Scholar
• Heider KH, Kuthan H, Stehle G, Munzert G. CD44v6: a target for antibody-based cancer therapy. Cancer Immunol Immunother. 2004;53(7):567–579.
   PubMed Web of Science ®Google Scholar
• Porcellini S, Asperti C, Corna S, et al. CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice. Front Immunol. 2020;11:99.
   PubMed Web of Science ®Google Scholar
• Casucci M, Nicolis Di Robilant B, Falcone L, et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood. 2013;122(20):3461–3472.
   PubMed Web of Science ®Google Scholar
• Tijink BM, Buter J, de Bree R, et al. A Phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006;12(20 Pt 1):6064–6072.
   PubMed Web of Science ®Google Scholar
• Crossland DL, Denning WL, Ang S, et al. Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models. Oncogene. 2018;37(27):3686–3697.
   PubMed Web of Science ®Google Scholar
• Jiang C, Zhao W, Qin M, Jin M, Chang L, Ma X. CD56-chimeric antigen receptor T-cell therapy for refractory/recurrent rhabdomyosarcoma: a 3.5-year follow-up case report. Medicine. 2019;98(43):e17572.
   PubMed Web of Science ®Google Scholar
• Xu T, Karschnia P, Cadilha BL, et al. In vivo dynamics and anti-tumor effects of EpCAM-directed CAR T-cells against brain metastases from lung cancer. Oncoimmunology. 2023;12(1):2163781.
   PubMed Web of Science ®Google Scholar
• Qin D, Li D, Zhang B, et al. Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models. Oncoimmunology. 2020;9(1):1806009.
   PubMed Web of Science ®Google Scholar
• Sanchez-Paulete AR, Mateus-Tique J, Mollaoglu G, et al. Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity. Cancer Immunol Res. 2022;10(11):1354–1369.
   PubMed Web of Science ®Google Scholar
• Liu J, Yang S, Cao B, et al. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. J Hematol Oncol. 2021;14(1):21.
   PubMed Web of Science ®Google Scholar
• Qin L, Zhao R, Chen D, et al. Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth. Biomark Res. 2020;8:19.
   PubMed Web of Science ®Google Scholar
• Yim J, Koh J, Kim S, et al. Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non-small-cell lung cancer. Eur J Cancer. 2020;133:74–85.
   PubMed Web of Science ®Google Scholar
• Li H, Harrison EB, Li H, et al. Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration. Nat Commun. 2022;13(1):2154.
   PubMed Web of Science ®Google Scholar
• Sharma SK, Pourat J, Abdel-Atti D, et al. Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. Cancer Res. 2017;77(14):3931–3941.
   PubMed Web of Science ®Google Scholar
• Chen X, Amar N, Zhu Y, et al. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth. J Immunother Cancer. 2020;8(1):46.
   Web of Science ®Google Scholar
• Jaspers JE, Khan JF, Godfrey WD, et al. IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. J Clin Invest. 2023:64.
   Web of Science ®Google Scholar
• Blackhall F, Jao K, Greillier L, et al. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: results From the Phase 3 TAHOE Study. J Thorac Oncol. 2021;16(9):1547–1558.
   PubMed Web of Science ®Google Scholar
• La HT, Tran DBT, Tran HM, Nguyen LT. Third-Generation Anti-CD47-Specific CAR-T Cells Effectively Kill Cancer Cells and Reduce the Genes Expression in Lung Cancer Cell Metastasis. J Immunol Res. 2021;2021:5575260.
   PubMed Web of Science ®Google Scholar
• Del Bufalo F, De Angelis B, Caruana I, et al. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. N Engl J Med. 2023;388(14):1284–1295.
   PubMed Web of Science ®Google Scholar
• Reppel L, Tsahouridis O, Akulian J, et al. Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer. J Immunother Cancer. 2022;10(1):54.
   Web of Science ®Google Scholar
• Sasaki T, Sakoda Y, Adachi K, Tokunaga Y, Tamada K. Therapeutic effects of anti-GM2 CAR-T cells expressing IL-7 and CCL19 for GM2-positive solid cancer in xenograft model. Cancer Med. 2023:23.
   Web of Science ®Google Scholar
• Li X, Zhu T, Wang R, et al. Genetically Programmable Vesicles for Enhancing CAR-T Therapy against Solid Tumors. Adv Mater. 2023;e2211138.
   PubMed Web of Science ®Google Scholar
• Ding J, Guyette S, Schrand B, et al. Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors. Oncoimmunology. 2023;12(1):2182058.
   PubMed Web of Science ®Google Scholar
• Zhao R, Cheng L, Jiang Z, et al. DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells. Oncoimmunology. 2019;8(1):e1509173.
   PubMed Web of Science ®Google Scholar
• Iwao K, Watanabe T, Fujiwara Y, et al. Isolation of a novel human lung-specific gene, LUNX, a potential molecular marker for detection of micrometastasis in non-small-cell lung cancer. Int J Cancer. 2001;91(4):433–437.
   PubMed Web of Science ®Google Scholar
• Hu Z, Zheng X, Jiao D, et al. LunX-CAR T Cells as a Targeted Therapy for Non-Small Cell Lung Cancer. Mol Ther Oncolytics. 2020;17:361–370.
   PubMed Web of Science ®Google Scholar
• Jie Y, Liu G, Feng L, et al. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies. Front Immunol. 2021;12:665970.
   PubMed Web of Science ®Google Scholar
• Martin AL, Anadon CM, Biswas S, et al. Olfactory Receptor OR2H1 Is an Effective Target for CAR T Cells in Human Epithelial Tumors. Mol Cancer Ther. 2022;21(7):1184–1194.
   PubMed Web of Science ®Google Scholar
• Nilsson MB, Yang Y, Heeke S, et al. CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. Cancer Cell. 2023;41(2):340–355 e346.
   PubMed Web of Science ®Google Scholar
• Pal S, Tran B, Haanen J, et al. 558 CTX130 allogeneic CRISPR-Cas9–engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: results from the phase 1 COBALT-RCC study. J ImmunoTherapy Cancer. 2022;10(Suppl 2):A584–A584.
   Google Scholar
• Mao Y, Fan W, Hu H, et al. MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells. J Hematol Oncol. 2019;12(1):106.
   PubMed Web of Science ®Google Scholar
• Kakarla S, Chow KK, Mata M, et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther. 2013;21(8):1611–1620.
   PubMed Web of Science ®Google Scholar
• Yang M, Tang X, Zhang Z, et al. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors. Theranostics. 2020;10(17):7622–7634.
   PubMed Web of Science ®Google Scholar
• Chu W, Zhou Y, Tang Q, et al. Bi-specific ligand-controlled chimeric antigen receptor T-cell therapy for non-small cell lung cancer. Biosci Trends. 2018;12(3):298–308.
   PubMed Web of Science ®Google Scholar
• Wilkie S, van Schalkwyk MC, Hobbs S, et al. Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling. J Clin Immunol. 2012;32(5):1059–1070.
   PubMed Web of Science ®Google Scholar
• Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 2013;5(215):215ra172.
   PubMed Web of Science ®Google Scholar
• Tokatlian T, Asuelime GE, Mock JY, et al. Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells. J Immunother Cancer. 2022;10(1).
   PubMed Web of Science ®Google Scholar
• Muliaditan T, Halim L, Whilding LM, et al. Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors. Cell Rep Med. 2021;2(12):100457.
   PubMedGoogle Scholar
• Guedan S, Posey AD, Shaw C, et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight. 2018;3(1):546.
   Web of Science ®Google Scholar
• Sonzogni O, Zak DE, Sasso MS, et al. T-SIGn tumor reengineering therapy and CAR T cells synergize in combination therapy to clear human lung tumor xenografts and lung metastases in NSG mice. Oncoimmunology. 2022;11(1):2029070.
   PubMed Web of Science ®Google Scholar
• Greco B, Malacarne V, De Girardi F, et al. Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies. Sci Transl Med. 2022;14(628):eabg3072.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Haas AR, Maus MV, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014;2(2):112–120.
   PubMed Web of Science ®Google Scholar
• Castelletti L, Yeo D, van Zandwijk N, Rasko JEJ. Anti-Mesothelin CAR T cell therapy for malignant mesothelioma. Biomark Res. 2021;9(1):11.
   PubMed Web of Science ®Google Scholar
• Adusumilli PS, Zauderer MG, Rusch VW, et al. Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: safety and preliminary efficacy in combination with anti-PD-1 agent. J Clin Oncol. 2019:53.
   Google Scholar
• Zhang C, Wang Z, Yang Z, et al. Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA(+) Metastatic Colorectal Cancers. Mol Ther. 2017;25(5):1248–1258.
   PubMed Web of Science ®Google Scholar
• Feng K, Guo Y, Dai H, et al. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. Sci China Life Sci. 2016;59(5):468–479.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Furlan SN, Jaeger-Ruckstuhl CA, et al. Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. Cancer Cell. 2021;39(2):193–208 e110.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Z, Ding Y, et al. Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients. J Cancer Res Clin Oncol. 2021;147(12):3725–3734.
   PubMed Web of Science ®Google Scholar
• Liu H, Ma Y, Yang C, et al. Severe delayed pulmonary toxicity following PD-L1-specific CAR-T cell therapy for non-small cell lung cancer. Clin Transl Immunol. 2020;9(10):e1154.
   PubMed Web of Science ®Google Scholar
• Feng K, Liu Y, Guo Y, et al. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. Protein Cell. 2018;9(10):838–847.
   PubMed Web of Science ®Google Scholar
• Byers L, Heymach J, Gibbons D, et al. 697 A phase 1 study of AMG 119, a DLL3-targeting, chimeric antigen receptor (CAR) T cell therapy, in relapsed/refractory small cell lung cancer (SCLC). J ImmunoTherapy Cancer. 2022;10(Suppl 2):A728–A728.
   Google Scholar
• Lin Y, Chen S, Zhong S, An H, Yin H, McGowan E. Phase 1 clinical trial of PD1 knockout anti-MUC1 CAR-T cells in the treatment of patients with non-small cell lung cancer. Ann Oncol. 2019;30:xi12–xi15.
   Google Scholar
• Haas AR, Tanyi JL, O’Hara MH, et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified t cells recognizing mesothelin in advanced solid cancers. Mol Ther. 2019;27(11):1919–1929.
   PubMed Web of Science ®Google Scholar
• Gutierrez R, Shah PD, Hamid O, et al. Phase I experience with first in class TnMUC1 targeted chimeric antigen receptor T-cells in patients with advanced TnMUC1 positive solid tumors. J Clin Oncol. 2021;39(15_suppl):e14513–e14513.
   Web of Science ®Google Scholar
• Qu J, Mei Q, Chen L, Zhou J. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives. Cancer Immunol Immunother. 2021;70(3):619–631.
   PubMed Web of Science ®Google Scholar
• Adusumilli PS, Amador AM, Chintala N, et al. Promoting functional persistence in solid tumor CAR T-cell therapy: mesothelin-targeted CAR (M28z1XXPD1DNR) with T-cell intrinsic PD1 dominant negative receptor. Ann Oncol. 2021;32:S1392–S1393.
   Web of Science ®Google Scholar
• Henry J, Oh D, Eskew J, et al. 728 Phase 1 study of P-MUC1C-ALLO1 allogeneic CAR-T cells in patients with epithelial-derived cancers. J ImmunoTherapy Cancer. 2022;10(Suppl 2):A761–A761.
   Google Scholar
• Spigel DR, Murthy H, Chumsri S, et al. Phase I study of LYL797, a ROR1-targeted CAR T-cell therapy with genetic and epigenetic reprogramming for the treatment of advanced solid tumors. Ann Oncol. 2022;33.
   PubMed Web of Science ®Google Scholar
• DiAndreth B, Hamburger AE, Xu H, Kamb A. The Tmod cellular logic gate as a solution for tumor-selective immunotherapy. Clin Immunol. 2022;241:109030.
   PubMed Web of Science ®Google Scholar
• Specht JM, Lee S, Turtle CJ, et al. Abstract CT131: a phase I study of adoptive immunotherapy for advanced ROR1+ malignancies with defined subsets of autologous T cells expressing a ROR1-specific chimeric antigen receptor (ROR1-CAR). Cancer Res. 2018;78:CT131.
   Web of Science ®Google Scholar
• Adusumilli PS, Zauderer MG, Riviere I, et al. A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab. Cancer Discov. 2021;11(11):2748–2763.
   PubMed Web of Science ®Google Scholar
• Gutierrez R, Shah PD, Hamid O, et al. Phase I experience with first in class TnMUC1 targeted chimeric antigen receptor T-cells in patients with advanced TnMUC1 positive solid tumors. J Clin Oncol. 2021;39(15S):e14513.
   Google Scholar
• Hayes TK, Meyerson M. Molecular portraits of lung cancer evolution. Nature. 2023.
   Web of Science ®Google Scholar
• Antonia SJ, Borghaei H, Ramalingam SS, et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol. 2019;20(10):1395–1408.
   PubMed Web of Science ®Google Scholar
• Yan X, Han L, Zhao R, Fatima S, Zhao L, Gao F. Prognosis value of IL-6, IL-8, and IL-1beta in serum of patients with lung cancer: a fresh look at interleukins as a biomarker. Heliyon. 2022;8(8):e09953.
   PubMed Web of Science ®Google Scholar
• Caruana I, Savoldo B, Hoyos V, et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med. 2015;21(5):524–529.
   PubMed Web of Science ®Google Scholar
• Obajdin J, Davies DM, Maher J. Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer. Clin Exp Immunol. 2020;202(1):11–27.
   PubMed Web of Science ®Google Scholar
• Okita R, Maeda A, Shimizu K, Nojima Y, Saisho S, Nakata M. Clinicopathological relevance of tumor expression of NK group 2 member D ligands in resected non-small cell lung cancer. Oncotarget. 2019;10(63):6805–6815.
   PubMedGoogle Scholar
• Davies DM, Foster J, Van Der Stegen SJ, et al. Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells. Mol Med. 2012;18:565–576.
   PubMed Web of Science ®Google Scholar
• Del Re M, Cucchiara F, Petrini I, et al. erbB in NSCLC as a molecular target: current evidences and future directions. ESMO Open. 2020;5(4):54.
   Web of Science ®Google Scholar
• Kosti P, Opzoomer JW, Larios-Martinez KI, et al. Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors. Cell Rep Med. 2021;2(4):100227.
   PubMedGoogle Scholar
• Glover M, Avraamides S, Maher J. How Can We Engineer CAR T Cells to Overcome Resistance? Biologics. 2021;15:175–198.
   PubMed Web of Science ®Google Scholar
• Hull CM, Maher J. Approaches for refining and furthering the development of CAR-based T cell therapies for solid malignancies. Expert Opin Drug Discov. 2021;16(10):1105–1117.
   PubMed Web of Science ®Google Scholar
• Shen L, Xiao Y, Tian J, Lu Z. Remodeling metabolic fitness: strategies for improving the efficacy of chimeric antigen receptor T cell therapy. Cancer Lett. 2022;529:139–152.
   PubMed Web of Science ®Google Scholar
• Zhu L, Liu J, Zhou G, et al. Remodeling of Tumor Microenvironment by Tumor-Targeting Nanozymes Enhances Immune Activation of CAR T Cells for Combination Therapy. Small. 2021;17(43):e2102624.
   PubMed Web of Science ®Google Scholar
• Ou Z, Dou X, Tang N, Liu G. Pressure increases PD-L1 expression in A549 lung adenocarcinoma cells and causes resistance to anti-ROR1 CAR T cell-mediated cytotoxicity. Sci Rep. 2022;12(1):6919.
   PubMed Web of Science ®Google Scholar
• Li S, Siriwon N, Zhang X, et al. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors. Clin Cancer Res. 2017;23(22):6982–6992.
   PubMed Web of Science ®Google Scholar
• Zhang L, Morgan RA, Beane JD, et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res. 2015;21(10):2278–2288.
   PubMed Web of Science ®Google Scholar
• Achkova DY, Beatson RE, Maher J. CAR T-Cell Targeting of Macrophage Colony-Stimulating Factor Receptor. Cells. 2022;11(14):2190.
   PubMed Web of Science ®Google Scholar
• Conde E, Vercher E, Soria-Castellano M, et al. Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants. J Immunother Cancer. 2021;9(11):687.
   Web of Science ®Google Scholar
• Lai J, Mardiana S, House IG, et al. Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. Nat Immunol. 2020;21(8):914–926.
   PubMed Web of Science ®Google Scholar
• Tatsumi T, Gambotto A, Robbins PD, Storkus WJ. Interleukin 18 gene transfer expands the repertoire of antitumor Th1-type immunity elicited by dendritic cell-based vaccines in association with enhanced therapeutic efficacy. Cancer Res. 2002;62(20):5853–5858.
   PubMed Web of Science ®Google Scholar
• Bhatia V, Kamat NV, Pariva TE, et al. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. Nat Commun. 2023;14(1):2041.
   PubMed Web of Science ®Google Scholar
• Jin C, Ma J, Ramachandran M, Yu D, Essand M. CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers. Nat Biomed Eng. 2022;6(7):830–841.
   PubMed Web of Science ®Google Scholar